Related Experiment Video
Updated: Aug 6, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
Scleroderma: it has been a long hard journey
P J Roberts-Thomson1, J G Walker
1Department of Immunology, Allergy and Arthritis, Flinders Medical Centre, Adelaide, South Australia, Australia. peter.roberts-thomson@flinders.edu.au
Abstract:
Progress in the understanding of the aetiopathogenesis of scleroderma (systemic sclerosis) has been painfully slow and this has greatly impeded the application of specific disease modifying treatments. This article provides a brief historical overview of scleroderma (including the important Australian contribution of Dr Alfred Barnett and colleagues--see accompanying article in this issue on pages 513-18), highlights some recent pathogenic developments and summarises some exciting new therapies. Cautious optimism can now be offered to scleroderma sufferers.
Related Concept Videos
Healing II: Complications
Atherosclerosis I: Introduction
Rheumatic Heart Disease I: Introduction
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Skin Diseases and Disorders
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Cirrhosis I: Introduction